$SYRE News
Last published 2d ago
- 2d agoSYRESpyre Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireWALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that management will participate in the following ...
- 6d agoSYRESpyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company committed to developing next-generation
- 6d agoSYRESpyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology...
- 1w agoSYRESpyre Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoSYRESpyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireAnnounced positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial ("SKYLINE"), completing proof-of-concept for all three monotherapies in inflammatory bowel disease ("IBD").
- 3w agoSYRESpyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026GlobeNewswireWALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in
- 1mo agoSYRESTIFEL 2026 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM - SPYRE THERAPEUTICS INCEarnings Call TranscriptsHey, good morning, everyone. Happy to have Cameron Turtle, CEO of Spire Therapeutics, with us for our next presentation of the morning. Maybe, Cameron, I'll kick it off to you, maybe a quick overview of SpIRE, and then I
- 1mo agoSYRESTIFEL 2026 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM - SPYRE THERAPEUTICS INCEarnings Call TranscriptsHey, good morning, everyone. Happy to have Cameron Turtle, CEO of Spire Therapeutics, with us for our next presentation of the morning. Maybe, Cameron, I'll kick it off to you, maybe a quick overview of SpIRE, and then I
- 2mo agoSYREWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - SPYRE THERAPEUTICS INCEarnings Call TranscriptsGood morning, everyone. Thanks for being here. My name is Yan Enzhu, and I'm one of the biotech analysts here at Wells Fargo. It is my great pleasure to be joined by the management team of Spire Therapeutics. With me her
- 2mo agoSYREWells Fargo 21st Annual Healthcare Conference - SPYRE THERAPEUTICS INCEarnings Call TranscriptsGood morning, everyone. Thanks for being here. My name is Yan Enzhu, and I'm one of the biotech analysts here at Wells Fargo. It is my great pleasure to be joined by the management team of Spire Therapeutics. With me her
- 2mo agoSYRESpyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD CombinationsGlobeNewswireSPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score Secondary endpoints included clinical
- 2mo agoSYRESpyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company committed to developing next-generation
- 2mo agoSYRESpyre Therapeutics to Participate in Upcoming September Investor ConferencesGlobeNewswireWALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in
- 2mo agoSYRESpyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072GlobeNewswireBoth doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50)
- 3mo agoSYRESpyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis SuppurativaGlobeNewswireSPY772 program aims to deliver best-in-indication efficacy and convenience in Hidradenitis Suppurativa through dual inhibition of TL1A and IL-17A/F in a long-acting coformulation Phase 2 SKYLIGHT trial designed to
- 3mo agoSYRESpyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company committed to developing next-generation
- 3mo agoSYRESpyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireAnnounced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial ("SKYLINE"), demonstrating best-in-class efficacy potential and a safety profile consistent with in-class
- 4mo agoSYRESpyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company committed to developing next-generation
- 5mo agoSYRESpyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis PatientsGlobeNewswireSPY002 met its primary endpoint with a statistically significant reduction of 10.7 points (p<0.0001) from baseline at Week 12 in Robart's Histopathology Index (RHI) score Secondary endpoints included clinical
- 5mo agoSYRESpyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate
- 5mo agoSYRESpyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpAGlobeNewswireEnrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial are complete Company reiterates expected Q3 2026 readout for rheumatoid arthritis (RA) and Q4 2026
- 5mo agoABVXORKASYREPhase 2 Data could Transform these Biotechs from Clinical Promise to Market ValidationGlobeNewswireDENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech
- 5mo agoSYRESpyre Therapeutics to Participate in Upcoming June Investor ConferencesGlobeNewswireWALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of
- 6mo agoSYRESpyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireAnnounced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class efficacy potential and a safety profile consistent with the α4β7 class Announced over-enrollment
- 6mo agoSYRESpyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to
- 7mo agoSYRESpyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 MillionGlobeNewswireWALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations
- 7mo agoSYRESpyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common StockGlobeNewswireWALTHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose
- 7mo agoSYRESpyre Therapeutics Announces Proposed Public Offering of its Common StockGlobeNewswireWALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose
- 7mo agoSYRESpyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis PatientsGlobeNewswireSPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p<0.0001) from baseline at Week 12 in Robart's Histopathology Index (RHI) score Secondary endpoints included clinical
- 7mo agoSYRESpyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026GlobeNewswireWALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of
- 7mo agoSYRESpyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations
- 8mo agoSYRESpyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026GlobeNewswireRecruitment for the rheumatoid arthritis (RA) sub-study of the SKYWAY basket trial is complete; Week 12 topline data now expected in Q3 2026 Recruitment for the psoriatic arthritis (PsA) and axial spondyloarthritis
- 8mo agoSYRESpyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations
- 8mo agoSYRESpyre Therapeutics to Participate in Upcoming March Investor ConferencesGlobeNewswireWALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of
- 8mo agoSYRESpyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswireOn track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second quarter,
- 8mo agoSYRESpyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination ApproachGlobeNewswireWALTHAM, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of
- 9mo agoSYRESpyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to
- 9mo agoSYRESpyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to
- 10mo agoSYRESpyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2GlobeNewswire"6 in '26" expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment complete ahead of schedule;
- 10mo agoSYRESpyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to
- 11mo agoSYRESpyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to
- 1y agoSYRESpyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to
- 1y agoSYRESpyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireReported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice annual
- 1y agoSYRESpyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 AntibodyGlobeNewswireSPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (α4β7 + IL-23) and SPY230
- 1y agoSYRESpyre Therapeutics to Participate in Upcoming November Investor ConferencesGlobeNewswireWALTHAM, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of
- 1y agoSYRESpyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025GlobeNewswireWALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of
- 1y agoSYRESpyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 MillionGlobeNewswireWALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose
- 1y agoSYRESpyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common StockGlobeNewswireWALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose
- 1y agoSYRESpyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded WarrantsGlobeNewswireWALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose
- 1y agoSYRESpyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025GlobeNewswireWALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic